Traveling w/ mixed emotions to @asco #asco25 this yr. Celebrating science & the yrs of dedication, work, & patient contributions to cancer clinical trials. But science itself is under attack — defunding of preclinical discovery work will end up slowing our clinical advances. 1/n

Day 2 #ASCO25 kicked off w/ a great discussion from Rana McKay, MD, FASCO of HIF-2α therapies in #RCC. Early success in refractory & VHL disease pave the way for earlier combination with IO/TKIs. Excited for Toni Choueiri, MD's oral abstract tomorrow. OncoDaily OncoAlert GU Oncology Now

The 5 yr follow up for adjuvant pembro in RCC (KN564): continued benefit- DFS (5yr 52% v61% - HR0.71) OS (5yr 82% vs 88% HR0.66). Maintained KM curve separation. No subgroup stands out. 18% TRAEs. Long term tox difficult to quantify but benifits seem to outweigh risks #ASCO25

Thankful to have been part of this #MedEd study highlighting the benefits of The Fellow On Call and TwoOncDocs podcasts in #HemOnc fellowships. See concurrent pub in Journal of Clinical Oncology! Vivek Patel, MD Karine Tawagi MD Ronak H. Mistry, DO Moriah Forster, MD ascopubs.org/doi/10.1200/OP…

So proud of this study and honored to be the senior author! What we’ve learned: The Fellow On Call and TwoOncDocs should be integrated into our heme/onc fellow education! 🔥 Link to this study: ascopubs.org/doi/10.1200/OP…

Here for a discussion on continuing advances in periooerative systemic therapy in muscle invasive #bladdercancer. Highlights to follow ⬇️ #ASCO25 OncoAlert Urology Today GU Oncology Now

Here for a discussion on continuing advances in periooerative systemic therapy in muscle invasive #bladdercancer. Highlights to follow ⬇️ #ASCO25 OncoAlert Urology Today GU Oncology Now

Niraparib plus Abi delays rPFS in HRR+ particularly BRCA2m mHSPC in AMPLITUDE! #ASCO25 #MedIQASCO25 HR 0.63 is clinically meaningful.

Home from #ASCO25 reflecting on transformative #ProstateCancer research. My thoughts on some of the most impactful studies⬇️ Thankful for new data to discuss with pts w/ hope for longer, healthier lives. ASCO Andrew Armstrong DCI Center for Prostate & Urologic Cancers OncoDaily UroToday.com OncoAlert

Home from ASCO25 reflecting on transformative Prostate Cancer Research - Dillon Cockrell, MD ASCO oncodaily.com/url/307789 #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer #CancerWorld #ASCO25 #ProstateCancerResearch

🚨 New findings in metastatic hormone-sensitive prostate cancer (#mHSPC)! 🚨 🔹 Over 12% of mHSPC patients harbor BRCA1/2 mutations, enriched in high-volume disease 🔹 Another 16% carry other homologous recombination repair (#HRR) gene alterations — overall HRR prevalence

Locations of metastases in and oncological outcomes of patients with #mCSPC: Real-world data from a multicenter study. Not all visceral mets are equal in #ProstateCancer. New multicenter mCSPC study shows patients with lung-only metastases have better outcomes than those with

🔬 CONTACT-02 Phase 3 Trial in mCRPC 🔬 📍 Patients with metastatic castration-resistant prostate cancer + extrapelvic soft-tissue mets post-ARPI 💊 Cabozantinib + Atezolizumab vs ARPI switch ✅ PFS: 6.3 vs 4.2 mo (HR 0.65, P=0.0007) ❌ OS: No significant difference (14.8 vs